www.cryocath.com Toronto Stock Exchange Symbol: CYT
MONTREAL, June 4 /CNW/ - CryoCath(R) Technologies Inc., the global leader
in cryotherapy products to treat cardiac arrhythmias, today announced the
introduction of Arctic Front(R) in Hong Kong. Arctic Front, the company's lead
product for the treatment of paroxysmal atrial fibrillation (PAF), is a unique
cryoablation balloon catheter that allows physicians to safely and effectively
isolate all four pulmonary veins in the treatment of PAF.
Dr. Ngai-Yin Chan, Head of the Electrophysiological Department at the
Princess Margaret Hospital, Hong Kong performed the first procedures on
May 28, 2008. Dr. Chan had previously attended the Arctic Front Masters
Program for the cryoballoon system in Bad Neustadt, Germany. Leadership of
this program is in the hands of Professor Dr. Burghard Schumacher and Dr.
Marcus Koller, Herz-und Gefass-Klinik. Professor Schumacher and Dr. Koller,
co-authors of The Cryoballoon Prospective Three Center Study, are two of the
most experienced users of the Arctic Front system and are responsible for
having trained in excess of sixty physicians on circumferential pulmonary vein
isolation with Arctic Front.
"In Arctic Front, we see the potential for a groundbreaking therapy in
the treatment of paroxysmal atrial fibrillation. Our belief in cryoablation
with the experience we have has been reinforced by a growing body of clinical
evidence in Europe and throughout the world," said Dr. Chan. "We are eager to
offer Arctic Front as a potentially safe and effective treatment to the
thousands of patients in Hong Kong suffering from atrial fibrillation."
"We are extremely proud to see Arctic Front expand into new markets
beyond Europe, first in Australia, and now in Hong Kong. With our rapidly
growing body of clinical evidence, we are confident that our Arctic Front
system will continue to broaden its user base," said Jan Keltjens, President
and CEO of CryoCath. "I am greatly encouraged by the support demonstrated by
leaders in Hong Kong's medical community. By strengthening our footprint in
Asia, we look forward to delivering the benefits of our breakthrough therapy
to a wider patient base, which will in turn accelerate the adoption of the
Arctic Front system worldwide."
Arctic Front will be exclusively distributed in Hong Kong by Pacific
Medical (HK) Co. Ltd.
About Arctic Front
Arctic Front is a minimally invasive cryo-balloon catheter designed
specifically to treat paroxysmal Atrial Fibrillation. This bi-directional,
double balloon catheter enables physicians to rapidly isolate all four
pulmonary veins for the treatment of AFib. Over 2,600 patients have been
treated in over 45 centres across Europe.
CryoCath - www.cryocath.com - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at www.sedar.com under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.
For further information:
For further information: visit our website at www.cryocath.com, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail: email@example.com